Supplementary Figure 3 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma | Synapse
September 10, 2025Open Access
Supplementary Figure 3 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Key Points
Gut metabolite profiles were significantly associated with CAR-T therapy outcomes in multiple myeloma patients.
Mean metabolite levels with standard deviation were presented for various metabolites observed before CAR-T infusion.
The analysis was based on fecal samples collected from multiple myeloma patients prior to CAR-T treatment.
Understanding microbiota roles may highlight new approaches for improving therapy responses in myeloma.
Abstract
Supplementary Figure S3 presents the pre-CAR T-cell infusion gut fecal metabolite profiles detected in multiple myeloma patients, showing means ± standard deviation for each metabolite.